European Surveillance of Infections in Cancer Patients - ESIC

Chemotherapy

Volumn 45, Issue 4, 1999, Pages 237-241

  Karthaus, M ^a   Buchheidt, D ^g   Hiddemann, W ^b   Donnelly, J P ^c   Krcmery, V ^d   Schiel, X ^b   Wilhelm, M ^e   Helmerking, M ^f  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d State Hospital   (Slovakia)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f Data Center   (Germany)

^g Dept of Hematology and Oncology ^*

Author keywords

Antimicrobial agents; Febrile neutropenia; Risk factors for complications

Indexed keywords

ANTIBIOTIC AGENT;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; DRUG SURVEILLANCE PROGRAM; FEBRILE NEUTROPENIA; HUMAN; INFECTION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RISK FACTOR;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; EUROPE; HUMANS; NEOPLASMS; OPPORTUNISTIC INFECTIONS; POPULATION SURVEILLANCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 0033043843     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007191     Document Type: Article

References (19)

1. Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, Pizzo P, Rolston KV, Shenep JL, Young LS: 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 1997;25: 551-573.
2. Klastersky J: 'Febrile neutropenia'. 20th anniversary of the EORTC Antimicrobial Therapy Cooperative Group. Brussels, December 1993. Support Care Cancer 1994;2:203-204.
3. Link H, Maschmeyer G, Meyer P, Hiddemann W, Stille W, Helmerking M, Adam D, for the study group of the Paul-Ehrlich Society for Chemotherapy. Interventional antimicrobial therapy in febrile neutropenic patients. Ann Hematol 1994;69:231-243.
4. Link H, Hiddemann W, Maschmeyer G, Buchheidt D, Glass B, Comely O, Wilhelm M, Helmerking M, Adam D and the PEG Study Group: Antimicrobial therapy in neutropenic patients with unexplained fever, PEG Study II (abstract LM-47. Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto 1997, pp 372-373.
5. Denning D, Meunier F, Cohen J, Marinas A, Krcmery V Jr: Invasive aspergillosis in cancer patients. J Infect 1998;33:332-340.
6. Viscoli C, Martino P, Marinus A, Krcmery V Jr, Meunier F: Survey of candidaemia in cancer patients. Clin Infect Dis 1997;23:1154.
7. Malik LA, Khan WA, Karim M, Aziz Z, Khan MA: Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: Results of a prospective randomized trial. Am J Med 1995;98: 224-231.
8. Karthaus M, Egerer G, Kullmann KH, Ritter J, Jürgens H: Ceftriaxone in the outpatient treatment of cancer patients with fever and neutropenia. Eur J Clin Microbiol Infect Dis 1998;17:501-504.
9. Karthaus M, Carratala J, Jürgens H, Ganser A: New strategies in the treatment of infectious complications in hematology and oncology: Is there a role for outpatient antibiotic treatment of febrile neutropenia? Chemotherapy 1998;44:427-435.
10. Rubinstein EB, Rolston K, Benjamin RS, Loewy J, Escalante C, Manzullo E, Hughes P, Moreland B, Fender A, Kennedy K, et al: Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993;71:3640-3646.
11. Anaissie EJ, Vadhan-Raj S: Is it time to redefine the management of febrile neutropenia in cancer patients? Am J Med 1995;98:221-223.
12. Cometta A, Calandra T, Gaya H, Zinner SH, De Bock R, Del Favero A, Bucaneve G, Crokaert F, Kern WV, Klastersky J, Langenacken I, Micozzi A, Padmos A, Paesmans M, Viscoli C, Glauser MP: Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Antimicrob Agents Chemother 1996; 40:1108-1115.
13. Cometta A, Glauser MP: Empiric antibiotic monotherapy with carbapenems in febrile neutropenia: A review. J Chemother 1996;8:375-381.
14. Pizzo PA, Hathorn JW, Hiemenz J, Browne M, Commers J, Cotton D, Gress J, Longo D, Marshall D, McKnight J, et al: A randomized trial comparing ceftazidine alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315:552-558.
15. Karthaus M, Südhoff T, Wolf HH, Kämpfe D, Egerer G, Ritter J, Peters G, Franke A, Heil G, Kullmann KH, Jürgens H: Ceftriaxone monotherapy in the treatment of low-risk febrile neutropenia. Chemotherapy 1998;44:343-354.
16. Bodey GP: Infection in cancer patients. A continuing association. Am J Med 1986;81:11-26.
17. Klastersky J, Zinner SH, Calandra T, Gaya H, Glauser MP, Meunier F, Rossi M, Schimpff SC, Tattersall M, Viscoli C: Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessions from four EORTC trials. Eur J Cancer Clin Oncol 1988;24(suppl 1):35-45.
18. Bodey GP, Buckley M, Sathe YS, Freireich EJ: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64: 328-340.
19. Talcott JA, Siegel RD, Finberg R, Goldman L: Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316-322.